Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1967301rdf:typepubmed:Citationlld:pubmed
pubmed-article:1967301lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:1967301lifeskim:mentionsumls-concept:C0543467lld:lifeskim
pubmed-article:1967301lifeskim:mentionsumls-concept:C0021853lld:lifeskim
pubmed-article:1967301lifeskim:mentionsumls-concept:C0006141lld:lifeskim
pubmed-article:1967301lifeskim:mentionsumls-concept:C1514559lld:lifeskim
pubmed-article:1967301lifeskim:mentionsumls-concept:C1317598lld:lifeskim
pubmed-article:1967301lifeskim:mentionsumls-concept:C0237881lld:lifeskim
pubmed-article:1967301lifeskim:mentionsumls-concept:C0220901lld:lifeskim
pubmed-article:1967301lifeskim:mentionsumls-concept:C0015737lld:lifeskim
pubmed-article:1967301lifeskim:mentionsumls-concept:C0750502lld:lifeskim
pubmed-article:1967301lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:1967301lifeskim:mentionsumls-concept:C1522673lld:lifeskim
pubmed-article:1967301lifeskim:mentionsumls-concept:C1709701lld:lifeskim
pubmed-article:1967301pubmed:issue1lld:pubmed
pubmed-article:1967301pubmed:dateCreated1990-2-22lld:pubmed
pubmed-article:1967301pubmed:abstractTextIn order to investigate the prognostic significance of erbB-2 overexpression, immunohistochemical staining for the erbB-2 protein was performed on sections from paraffin blocks of 292 primary invasive breast cancers obtained from women enrolled in the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-06. Positive reaction indicative of erbB-2 overexpression was observed on tumor cells in 62 (21%) samples. Women whose cancers were judged to have erbB-2 overexpression had a significantly worse overall survival (P = .0012) with twice the mortality rate of women without detectable erbB-2 expression. No statistically significant effect was evident for disease-free survival (P = .22). In multivariate analysis, detection of erbB-2 overexpression was the second most predictive independent variable for survival after nodal status. Overexpression of erbB-2 was more common among tumors of poor nuclear grade (29%) than those of good nuclear grade (12%). The association of erbB-2 overexpression with decreased survival was evident only among women with tumors of good nuclear grade. In this subgroup, erbB-2 overexpression was associated with an approximately fivefold increase in mortality rate (P = .00001). The combined predictive value of erbB-2 overexpression and nuclear grade was evident regardless of their lymph node status. These results provide evidence that detection of erbB-2 overexpression may be an independent prognostic variable for patient survival. Moreover, when combined with evaluation of nuclear grade, it may be possible to use immunostaining for erbB-2 protein to identify patients at increased risk from within a relatively low-risk group.lld:pubmed
pubmed-article:1967301pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1967301pubmed:languageenglld:pubmed
pubmed-article:1967301pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1967301pubmed:citationSubsetIMlld:pubmed
pubmed-article:1967301pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1967301pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1967301pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1967301pubmed:statusMEDLINElld:pubmed
pubmed-article:1967301pubmed:monthJanlld:pubmed
pubmed-article:1967301pubmed:issn0732-183Xlld:pubmed
pubmed-article:1967301pubmed:authorpubmed-author:SchlessingerJ...lld:pubmed
pubmed-article:1967301pubmed:authorpubmed-author:LippmanM EMElld:pubmed
pubmed-article:1967301pubmed:authorpubmed-author:KingC RCRlld:pubmed
pubmed-article:1967301pubmed:authorpubmed-author:FisherBBlld:pubmed
pubmed-article:1967301pubmed:authorpubmed-author:FisherE RERlld:pubmed
pubmed-article:1967301pubmed:authorpubmed-author:RedmondCClld:pubmed
pubmed-article:1967301pubmed:authorpubmed-author:PaimUUlld:pubmed
pubmed-article:1967301pubmed:authorpubmed-author:HazanRRlld:pubmed
pubmed-article:1967301pubmed:authorpubmed-author:SassR ERElld:pubmed
pubmed-article:1967301pubmed:issnTypePrintlld:pubmed
pubmed-article:1967301pubmed:volume8lld:pubmed
pubmed-article:1967301pubmed:ownerNLMlld:pubmed
pubmed-article:1967301pubmed:authorsCompleteYlld:pubmed
pubmed-article:1967301pubmed:pagination103-12lld:pubmed
pubmed-article:1967301pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:1967301pubmed:meshHeadingpubmed-meshheading:1967301-...lld:pubmed
pubmed-article:1967301pubmed:meshHeadingpubmed-meshheading:1967301-...lld:pubmed
pubmed-article:1967301pubmed:meshHeadingpubmed-meshheading:1967301-...lld:pubmed
pubmed-article:1967301pubmed:meshHeadingpubmed-meshheading:1967301-...lld:pubmed
pubmed-article:1967301pubmed:meshHeadingpubmed-meshheading:1967301-...lld:pubmed
pubmed-article:1967301pubmed:meshHeadingpubmed-meshheading:1967301-...lld:pubmed
pubmed-article:1967301pubmed:meshHeadingpubmed-meshheading:1967301-...lld:pubmed
pubmed-article:1967301pubmed:meshHeadingpubmed-meshheading:1967301-...lld:pubmed
pubmed-article:1967301pubmed:meshHeadingpubmed-meshheading:1967301-...lld:pubmed
pubmed-article:1967301pubmed:meshHeadingpubmed-meshheading:1967301-...lld:pubmed
pubmed-article:1967301pubmed:meshHeadingpubmed-meshheading:1967301-...lld:pubmed
pubmed-article:1967301pubmed:meshHeadingpubmed-meshheading:1967301-...lld:pubmed
pubmed-article:1967301pubmed:meshHeadingpubmed-meshheading:1967301-...lld:pubmed
pubmed-article:1967301pubmed:year1990lld:pubmed
pubmed-article:1967301pubmed:articleTitlePathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.lld:pubmed
pubmed-article:1967301pubmed:affiliationMedical Breast Cancer Section, National Cancer Institute, Bethesda, MD.lld:pubmed
pubmed-article:1967301pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1967301pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:1967301pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1967301lld:pubmed
More...